← Back to guidelines
Cardiology7 papers

Uvular hypertrophy

Last edited: 4/22/2026

Overview

Uvular hypertrophy refers to the enlargement of the uvula, which can lead to symptoms such as dysphagia, snoring, and sleep apnea. It is often associated with anatomical variations or secondary to other conditions like chronic irritation or inflammation 1.

Diagnosis

  • Clinical examination revealing enlarged uvula size
  • Flexible nasopharyngoscopy to visualize the uvula and assess for associated anatomical abnormalities
  • Imaging studies (e.g., MRI, CT) may be considered in complex cases to rule out other pathologies 1
  • Management

  • First-line treatments: Address underlying causes (e.g., reducing irritants, managing GERD)
  • Adjunctive treatments: Surgical intervention (uvulectomy) may be necessary for symptomatic relief in severe cases 1
  • Special Populations

  • Elderly: Consider comorbidities and functional status when evaluating surgical options 1
  • Comorbidities: Management should focus on alleviating symptoms impacting sleep apnea or swallowing difficulties, potentially integrating care with ENT specialists 1
  • Key Recommendations

  • Identify and manage underlying causes contributing to uvular hypertrophy to prevent symptom exacerbation (Evidence: Expert opinion) 1
  • Consider flexible nasopharyngoscopy for definitive diagnosis and assessment of anatomical impact 1
  • Evaluate surgical intervention (uvulectomy) for patients with significant symptoms refractory to conservative management (Evidence: Expert opinion) 1
  • References

    1 Maïga A, Mourier G, Quinton L, Rouget C, Gales C, Denis C et al.. G protein-coupled receptors, an unexploited animal toxin targets: Exploration of green mamba venom for novel drug candidates active against adrenoceptors. Toxicon : official journal of the International Society on Toxinology 2012. link

    Original source

    1. [1]
      G protein-coupled receptors, an unexploited animal toxin targets: Exploration of green mamba venom for novel drug candidates active against adrenoceptors.Maïga A, Mourier G, Quinton L, Rouget C, Gales C, Denis C et al. Toxicon : official journal of the International Society on Toxinology (2012)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG